Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Apoptosis, Combination therapy, Adult, MPN, Clinical Practice (Health Services and Quality), Drug development, Clinical Research, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Treatment Considerations, Adverse Events, Myeloid Malignancies, Study Population, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Apoptosis, Combination therapy, Adult, MPN, Clinical Practice (Health Services and Quality), Drug development, Clinical Research, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Treatment Considerations, Adverse Events, Myeloid Malignancies, Study Population, Human
Monday, December 9, 2024: 4:30 PM-6:00 PM
Harbor Ballroom DEFG
(Manchester Grand Hyatt San Diego)
Moderators:
Lindsay A.M. Rein, MD, Duke Cancer Institute
and
Jean-Jacques Kiladjian, MD, PhD, Paris Cité University
Disclosures:
Rein: Abbvie: Consultancy; Sobi: Consultancy; DAVA Oncology: Other: Speaker, conference participant; Incyte: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Morphpsys: Consultancy; Novartis: Consultancy, Honoraria, Other: Site Principal Investigator for clinical trial, Research Funding; Sumitomo Dainippon Pharma Oncology: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Cogent Biosciences: Consultancy, Other: Site Principal Investigator for clinical trial, Research Funding; Protagonist: Other: Site Principal Investigator for clinical trial, Research Funding; Geron: Other: Site Principal Investigator for clinical trial, Research Funding; Blueprints Medicine: Other: Site Principal Investigator for clinical trial, Research Funding; Merck: Other: Site Principal Investigator for clinical trial, Research Funding; PharmaEssentia: Other: Site Principal Investigator for clinical trial, Research Funding; Karyopharm: Other: Site Principal Investigator for clinical trial, Research Funding; Telios Pharma: Research Funding; Silence Therapeutics: Research Funding. Kiladjian: Novartis: Consultancy; GSK: Consultancy; AOP Health: Consultancy; Incyte: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria; PharmaEssentia: Honoraria.
This session focuses on the latest advancements in treating myeloproliferative neoplasms (MPNs), with a spotlight on innovative therapies and key clinical trials. Presentations will cover a range of emerging treatments in combination with ruxolitinib for myelofibrosis to the use of novel therapies in various MPN and MDS/MPN subtypes. Attendees will gain insights into the efficacy, safety, and clinical benefits of these novel therapies, particularly for patients with suboptimal responses to existing treatments or those who are treatment-naive. By focusing on cutting-edge clinical studies and combination therapies, this session aims to provide healthcare professionals with the knowledge to optimize treatment strategies, improve patient outcomes, and advance care across the spectrum of myeloproliferative neoplasms.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH